Increased expression of c-FLIP has been found in many human malignancies, such as colon, ovarian, breast and prostate cancer, as well as glioblastoma, and has been shown to be involved in resistance to CD95/Fas and TRAIL receptor-induced apoptosis [23,24,25,26]. Here, CFLAR is linked to prostate carcinoma.